biotechnology

Exclusive John Wilkerson and Rachel Cohrs Zhang

STAT Plus: Generic drug lobby taps former BIO exec as new CEO

The Readout Elaine Chen

STAT Plus: The science behind Summit’s success, 23andMe’s fate, and more biotech news updates

Exclusive Jonathan Wosen

STAT Plus: The little-known Chinese biotech whose cancer drug beat Keytruda has global ambitions

Pharmalot Ed Silverman

STAT Plus: Baltimore claims Biogen ‘bribed’ PBMs to favor its pricey MS drug over generics

Biotech Stella Tannenbaum — The Boston Globe

STAT Plus: Bluebird Bio is laying off 25% of its workers to cut costs

Politics Rachel Cohrs Zhang and Elaine Chen

STAT Plus: Sanders says PBMs won’t penalize Novo for cutting Ozempic, Wegovy prices

Biotech Matthew Herper

STAT Plus: Amid push to redefine itself, Sanofi names new chief scientific officer

The Readout Elaine Chen

STAT Plus: Metsera’s GLP-1 drug has potential for monthly dosing, new data show

Biotech Adam Feuerstein

STAT Plus: Regeneron’s Eylea biosimilar fight heats up

Biotech Brittany Trang

STAT Plus: Novartis strikes AI drug development deal with Generate:Biomedicines

Biotech Adam Feuerstein

STAT Plus: Risky bet by Biogen and UCB on systemic lupus drug appears to pay off, data show

The Readout Meghana Keshavan

STAT Plus: The biotech news you need to start the week

Exclusive Rachel Cohrs Zhang

STAT Plus: A mysterious anti ‘Big Pharma’ bus is barnstorming swing states

Politics John Wilkerson

STAT Plus: Wegovy is among drugs set to be targeted in the next round of Medicare price negotiations, researchers say

Pharma Rachel Cohrs Zhang

STAT Plus: PhRMA scores a small win in legal challenge to Medicare’s drug price negotiation

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Biotech Elaine Chen

STAT Plus: Novo’s new obesity drug shows modest results, raises concerns of psychiatric side effects

The Readout Meghana Keshavan

STAT Plus: Are generalist investors good or bad for biotech?

Exclusive John Wilkerson

STAT Plus: Cassidy seeks to exempt small biotechs from Medicare drug price negotiation 

The Readout LOUD Allison DeAngelis, Adam Feuerstein, and Elaine Chen

Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates

Pharmalot Ed Silverman

STAT Plus: Lawmakers urge U.S. Patent Office and drugmakers to correct patent mistakes

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: Corbus shares will soar or dive soon. Here’s why

The Readout Elaine Chen

STAT Plus: The Fed cut rates and biotech stocks… didn’t do much

Biotech Allison DeAngelis

STAT Plus: A new cell therapy company takes its vision from four founders, and its skin from George Church

Biotech Elaine Chen

STAT Plus: Corbus sees Novo’s controversial obesity approach as a ticket to a blockbuster

Biotech Jonathan Wosen

STAT Plus: Biotech feud over the multibillion-dollar cancer blood test market spills onto social media

The Readout Elaine Chen

STAT Plus: Bernie Sanders keeps the heat on Novo’s high prices

Biotech Allison DeAngelis

STAT Plus: Roivant strikes another deal, selling dermatology spinoff to Organon in deal worth $1.2 billion

The Readout Elaine Chen

STAT Plus: FDA formalizes protocol for international cancer trials